This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: secondary care

Adapting cardiovascular disease care to the ‘new norm’ of the COVID-19 era: same standard, different delivery

December 2020 Br J Cardiol 2020;27(suppl 2):S2–S16 doi:10.5837/bjc2020.s05

Adapting cardiovascular disease care to the ‘new norm’ of the COVID-19 era: same standard, different delivery

Martin R Cowie, Matthew Fay, Jo Jerrome, Abhishek Joshi, Jim Moore, Helen Williams

Abstract

Introduction to the steering committee From left to right: Professor Martin Cowie, Dr Matthew Fay, Ms Jo Jerrome,Dr Abhishek Joshi, Dr Jim Moore, Ms Helen Williams Conflicts of interest The steering committe received speaking and consultation fees from Bayer plc. MRC provides consultancy advice to Abbott, AstraZeneca, Bayer, Boston Scientific, Medtronic, Novartis, Roche Diagnostics and Servier. MF has received speaker honoraria, conference sponsorship, unrestricted educational grants, and/or attended meetings sponsored by AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Medtronic, Novartis, Pfizer, Roche, Sanofi-Aventis, and S

| Full text

May 2007 Br J Cardiol 2007;14:125-126

The new SIGN guidance on CHD and its implications for secondary care

Kevin Jennings, Lewis Ritchie

Abstract

No content available

| Full text

April 2002 Br J Cardiol 2002;9:

The evidence for secondary prevention and cardiac rehabilitation in hospitals

Jane Flint

Abstract

No content available

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now